Synergistic Effects of Combination Therapy with AKT and mTOR Inhibitors on Bladder Cancer Cells
Open Access
- 18 April 2020
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (8), 2825
- https://doi.org/10.3390/ijms21082825
Abstract
Despite comprehensive genomic analyses, no targeted therapies are approved for bladder cancer. Here, we investigate whether a single and combination therapy with targeted agents exert antitumor effects on bladder cancer cells through genomic alterations using a three-dimensional (3D) high-throughput screening (HTS) platform. Seven human bladder cancer cell lines were used to screen 24 targeted agents. The effects of 24 targeted agents were dramatically different according to the genomic alterations of bladder cancer cells. BEZ235 (dual phosphatidylinositol-3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitor) showed antitumor effects against most cell lines, while AZD2014 (mTOR inhibitor) had an IC50 value lower than 2 μM in 5637, J82, and RT4 cell lines. AZD5363 (protein kinase B (AKT) inhibitor) exerted antitumor effects on 5637, J82, and 253J-BV cells. J82 cells (PI3KCA and mTOR mutations) were sensitive to AZD5363, AZD2014, and BEZ235 alone or in AZD5363/AZD2014 and AZD5363/BEZ235 combinations. Although all single drugs suppressed cell proliferation, the combination of drugs exhibited synergistic effects on cell viability and colony formation. The synergistic effects of the combination therapy on the PI3K/Akt/mTOR pathway, apoptosis, and EMT were evident in Western blotting. Thus, the 3D culture-based HTS platform could serve as a useful preclinical tool to evaluate various drug combinations.Funding Information
- Korea Health Industry Development Institute (HI14C2750, HI14C3418)
This publication has 36 references indexed in Scilit:
- Phase II study of everolimus in metastatic urothelial cancerBJU International, 2013
- Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: The discovery of AZD8055 and AZD2014Bioorganic & Medicinal Chemistry Letters, 2013
- Differentiating mTOR inhibitors in renal cell carcinomaCancer Treatment Reviews, 2013
- Preclinical Pharmacology of AZD5363, an Inhibitor of AKT: Pharmacodynamics, Antitumor Activity, and Correlation of Monotherapy Activity with Genetic BackgroundMolecular Cancer Therapeutics, 2012
- Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast CancerThe New England Journal of Medicine, 2012
- mTOR Kinase Inhibition Causes Feedback-Dependent Biphasic Regulation of AKT SignalingCancer Discovery, 2011
- Everolimus for Advanced Pancreatic Neuroendocrine TumorsThe New England Journal of Medicine, 2011
- Cell Signaling by Receptor Tyrosine KinasesCell, 2010
- Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activityMolecular Cancer Therapeutics, 2008
- Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients With Bladder CancerJournal of Clinical Oncology, 2005